RESUMEN
Flavin-dependent monooxygenases catalyze a wide variety of redox reactions in important biological processes and are responsible for the synthesis of highly complex natural products. Although much has been learned about FMO chemistry in the last ~80 years of research, several aspects of the reactions catalyzed by these enzymes remain unknown. In this review, we summarize recent advancements in the flavin-dependent monooxygenase field including aspects of flavin dynamics, formation and stabilization of reactive species, and the hydroxylation mechanism. Novel catalysis of flavin-dependent N-oxidases involving consecutive oxidations of amines to generate oximes or nitrones is presented and the biological relevance of the products is discussed. In addition, the activity of some FMOs have been shown to be essential for the virulence of several human pathogens. We also discuss the biomedical relevance of FMOs in antibiotic resistance and the efforts to identify inhibitors against some members of this important and growing family enzymes.
Asunto(s)
Flavoproteínas/química , Oxigenasas de Función Mixta/química , Animales , Bacterias/enzimología , Biocatálisis , Descubrimiento de Drogas , Inhibidores Enzimáticos/química , Inhibidores Enzimáticos/farmacología , Flavinas/química , Flavinas/metabolismo , Flavoproteínas/antagonistas & inhibidores , Flavoproteínas/metabolismo , Humanos , Hidroxilación , Oxigenasas de Función Mixta/antagonistas & inhibidores , Oxigenasas de Función Mixta/metabolismo , Unión Proteica , Conformación ProteicaRESUMEN
The flavoenzyme dihydroorotate dehydrogenase catalyzes the stereoselective oxidation of (S)-dihydroorotate to orotate in the fourth of the six conserved enzymatic reactions involved in the de novo pyrimidine biosynthetic pathway. Inhibition of pyrimidine metabolism by selectively targeting DHODHs has been exploited in the development of new therapies against cancer, immunological disorders, bacterial and viral infections, and parasitic diseases. Through a chronological narrative, this review summarizes the efforts of the scientific community to achieve our current understanding of structural and biochemical properties of DHODHs. It also attempts to describe the latest advances in medicinal chemistry for therapeutic development based on the selective inhibition of DHODH, including an overview of the experimental techniques used for ligand screening during the process of drug discovery.
Asunto(s)
Flavoproteínas , Oxidorreductasas actuantes sobre Donantes de Grupo CH-CH , Animales , Infecciones Bacterianas/tratamiento farmacológico , Infecciones Bacterianas/enzimología , Dihidroorotato Deshidrogenasa , Descubrimiento de Drogas , Inhibidores Enzimáticos/química , Inhibidores Enzimáticos/uso terapéutico , Flavoproteínas/antagonistas & inhibidores , Flavoproteínas/química , Flavoproteínas/metabolismo , Humanos , Enfermedades del Sistema Inmune/tratamiento farmacológico , Enfermedades del Sistema Inmune/enzimología , Neoplasias/tratamiento farmacológico , Neoplasias/enzimología , Oxidorreductasas actuantes sobre Donantes de Grupo CH-CH/antagonistas & inhibidores , Oxidorreductasas actuantes sobre Donantes de Grupo CH-CH/química , Oxidorreductasas actuantes sobre Donantes de Grupo CH-CH/metabolismo , Enfermedades Parasitarias/tratamiento farmacológico , Enfermedades Parasitarias/enzimología , Pirimidinas/química , Pirimidinas/metabolismo , Virosis/tratamiento farmacológico , Virosis/enzimologíaRESUMEN
BACKGROUND/AIMS: Motility is a feature of many pathogens that contributes to the migration and dispersion of the infectious agent. Whether gentamycin has a post-antibiotic effect (PAE) on the swarming and swimming motility of Escherichia coli (E. coli) remains unknown. In this study, we aimed to examine whether short-term pretreatment of sub-inhibitory concentrations of gentamycin alter motility of E. coli and the mechanisms involved therein. METHODS: After exposure to sub-inhibitory concentrations (0.8 µg/ml) of gentamicin, the swarming and swimming motility of E. coli was tested in semi-solid media. Real-time PCR was used to detect the gene expression of succinate dehydrogenase (SDH). The production of SDH and fumarate by E. coli pretreated with or without gentamycin was measured. Fumarate was added to swarming agar to determine whether fumarate could restore the swarming motility of E. coli. RESULTS: After pretreatment of E. coli with sub-inhibitory concentrations of gentamycin, swarming motility was repressed in the absence of growth inhibition. The expression of all four subunits of SDH was down-regulated, and the intracellular concentration of SDH and fumarate, produced by E. coli, were both decreased. Supplementary fumarate could restore the swarming motility inhibited by gentamycin. A selective inhibitor of SDH (propanedioic acid) could strongly repress the swarming motility. CONCLUSION: Sub-inhibitory concentrations of gentamycin inhibits the swarming motility of E. coli. This effect is mediated by a reduction in cellular fumarate caused by down-regulation of SDH. Gentamycin may be advantageous for treatment of E. coli infections.
Asunto(s)
Antibacterianos/farmacología , Proteínas Bacterianas/antagonistas & inhibidores , Escherichia coli/efectos de los fármacos , Flavoproteínas/antagonistas & inhibidores , Regulación Bacteriana de la Expresión Génica , Gentamicinas/farmacología , Subunidades de Proteína/antagonistas & inhibidores , Proteínas Bacterianas/genética , Proteínas Bacterianas/metabolismo , Escherichia coli/enzimología , Escherichia coli/genética , Escherichia coli/crecimiento & desarrollo , Flavoproteínas/genética , Flavoproteínas/metabolismo , Fumaratos/metabolismo , Malonatos/farmacología , Pruebas de Sensibilidad Microbiana , Movimiento/efectos de los fármacos , Subunidades de Proteína/genética , Subunidades de Proteína/metabolismo , Transducción de Señal , Ácido Succínico/metabolismo , Factores de TiempoRESUMEN
PURPOSE: The clinical management of colorectal cancer patients has significantly improved because of the identification of novel therapeutic targets such as EGFR and VEGF. Because rapid tumor proliferation is associated with poor patient prognosis, here we characterized the transcriptional signature of rapidly proliferating colorectal cancer cells in an attempt to identify novel candidate therapeutic targets. EXPERIMENTAL DESIGN: The doubling time of 52 colorectal cancer cell lines was determined and genome-wide expression profiling of a subset of these lines was assessed by microarray analysis. We then investigated the potential of genes highly expressed in cancer cells with faster growth as new therapeutic targets. RESULTS: Faster proliferation rates were associated with microsatellite instability and poorly differentiated histology. The expression of 1,290 genes was significantly correlated with the growth rates of colorectal cancer cells. These included genes involved in cell cycle, RNA processing/splicing, and protein transport. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and protoporphyrinogen oxidase (PPOX) were shown to have higher expression in faster growing cell lines and primary tumors. Pharmacologic or siRNA-based inhibition of GAPDH or PPOX reduced the growth of colon cancer cells in vitro. Moreover, using a mouse xenograft model, we show that treatment with the specific PPOX inhibitor acifluorfen significantly reduced the growth of three of the seven (42.8%) colon cancer lines investigated. CONCLUSIONS: We have characterized at the transcriptomic level the differences between colorectal cancer cells that vary in their growth rates, and identified novel candidate chemotherapeutic targets for the treatment of colorectal cancer.
Asunto(s)
Neoplasias Colorrectales/genética , Flavoproteínas/biosíntesis , Gliceraldehído-3-Fosfato Deshidrogenasas/biosíntesis , Proteínas Mitocondriales/biosíntesis , Proteínas de Neoplasias/biosíntesis , Protoporfirinógeno-Oxidasa/biosíntesis , Animales , Ciclo Celular/genética , Proliferación Celular/genética , Neoplasias Colorrectales/tratamiento farmacológico , Neoplasias Colorrectales/patología , Femenino , Flavoproteínas/antagonistas & inhibidores , Flavoproteínas/genética , Regulación Neoplásica de la Expresión Génica , Gliceraldehído-3-Fosfato Deshidrogenasas/genética , Células HCT116 , Humanos , Masculino , Ratones , Proteínas Mitocondriales/antagonistas & inhibidores , Proteínas Mitocondriales/genética , Terapia Molecular Dirigida , Proteínas de Neoplasias/genética , Nitrobenzoatos/administración & dosificación , Transporte de Proteínas/genética , Protoporfirinógeno-Oxidasa/antagonistas & inhibidores , Protoporfirinógeno-Oxidasa/genética , Empalme del ARN/genética , ARN Interferente Pequeño , Transducción de Señal , Ensayos Antitumor por Modelo de XenoinjertoRESUMEN
Flavoprotein autofluorescence signals attributed to neuronal metabolism have been used to assess synaptic function. Here, we characterized flavoprotein autofluorescence responses in the molecular layer of rat cerebellar slices. High frequency stimulation elicited a transient fluorescence increase (peak phase) that was followed by a longer-lasting fluorescence decrease (valley phase). The peak phase was restricted to the molecular layer, whereas the valley phase extended into the Purkinje cell layer and a portion of the granule cell layer. Responses were abolished by either the Na(+) channel antagonist, tetrodotoxin, or a combination of the AMPA receptor antagonists, NBQX and GIKI-53655, and were also reduced by a flavoprotein inhibitor (diphenyleneiodonium). These findings are consistent with responses being mediated by an increase in mitochondrial activity triggered by increased energy demands evoked by AMPA receptor-mediated synaptic transmission. The GABAA receptor antagonist picrotoxin did not significantly influence evoked responses. Likewise, exogenous application of ethanol, at concentrations known to increase GABAA receptor-mediated synaptic transmission at Purkinje cells, did not modify peak responses. These observations indicate that flavoprotein autofluorescence imaging could be useful to assess the coupling between glutamatergic synaptic transmission and neuronal metabolism in cerebellar slices.
Asunto(s)
Cerebelo/fisiología , Flavoproteínas/metabolismo , Neuronas/fisiología , Animales , Axones/efectos de los fármacos , Axones/fisiología , Cerebelo/citología , Estimulación Eléctrica , Etanol/farmacología , Flavoproteínas/antagonistas & inhibidores , Fluorescencia , Técnicas In Vitro , Masculino , Neuronas/efectos de los fármacos , Oxidación-Reducción , Células de Purkinje/efectos de los fármacos , Células de Purkinje/fisiología , Ratas Sprague-Dawley , Receptores AMPA/antagonistas & inhibidores , Receptores AMPA/fisiología , Transmisión SinápticaRESUMEN
While the presentation mechanism of antigenic peptides derived from exogenous proteins by MHC class II molecules is well understood, relatively little is known about the presentation mechanism of endogenous MHC class II-restricted antigens. We therefore screened a chemical library of 200 compounds derived from natural products to identify inhibitors of the presentation of endogenous MHC class II-restricted antigens. We found that pyrenocine B, a compound derived from the fungus Pyrenochaeta terrestris, inhibits presentation of endogenous MHC class II-restricted minor histocompatibility antigen IL-4 inducible gene 1 (IL4I1) by primary dendritic cells (DCs). Phage display screening and surface plasmon resonance (SPR) analysis were used to investigate the mechanism of suppressive action by pyrenocine B. EpsinR, a target molecule for pyrenocine B, mediates endosomal trafficking through binding of soluble N-ethylmaleimide-sensitive factor attachment protein receptors (SNAREs). Lentiviral-mediated short hairpin (sh) RNA downregulation of EpsinR expression in DCs resulted in a decrease in the responsiveness of CD4+ T cells. Our data thus suggest that EpsinR plays a role in antigen presentation, which provides insight into the mechanism of presentation pathway of endogenous MHC class II-restricted antigen.
Asunto(s)
Proteínas Adaptadoras del Transporte Vesicular/inmunología , Presentación de Antígeno/efectos de los fármacos , Antígenos de Histocompatibilidad Clase II/inmunología , Proteínas Adaptadoras del Transporte Vesicular/antagonistas & inhibidores , Proteínas Adaptadoras del Transporte Vesicular/genética , Animales , Presentación de Antígeno/inmunología , Linfocitos T CD4-Positivos/inmunología , Técnicas de Visualización de Superficie Celular , Células Dendríticas/inmunología , Flavoproteínas/antagonistas & inhibidores , Flavoproteínas/biosíntesis , Proteínas Fúngicas/farmacología , L-Aminoácido Oxidasa , Activación de Linfocitos/inmunología , Ratones , Ratones Endogámicos C3H , Ratones Endogámicos C57BL , Pironas/farmacología , Interferencia de ARN , ARN Interferente Pequeño , Proteínas SNARE/inmunología , Resonancia por Plasmón de SuperficieAsunto(s)
Diseño de Fármacos , Flavoproteínas/antagonistas & inhibidores , Proteínas Mitocondriales/antagonistas & inhibidores , Porfiria Variegata/tratamiento farmacológico , Porfiria Variegata/enzimología , Protoporfirinógeno-Oxidasa/antagonistas & inhibidores , Flavoproteínas/metabolismo , Humanos , Proteínas Mitocondriales/metabolismo , Terapia Molecular Dirigida , Protoporfirinógeno-Oxidasa/metabolismoRESUMEN
The potential of flavoproteins as targets of pharmacological treatments is immense. In this review we present an overview of the current research progress on medical interventions based on flavoproteins with a special emphasis on cancer, infectious diseases, and neurological disorders.
Asunto(s)
Flavinas/metabolismo , Flavoproteínas/metabolismo , Animales , Enfermedades Transmisibles/tratamiento farmacológico , Enfermedades Transmisibles/etiología , Enfermedades Transmisibles/metabolismo , Inhibidores Enzimáticos/farmacología , Inhibidores Enzimáticos/uso terapéutico , Flavoproteínas/antagonistas & inhibidores , Humanos , Trastornos Mentales/tratamiento farmacológico , Trastornos Mentales/metabolismo , Neoplasias/tratamiento farmacológico , Neoplasias/metabolismo , Enfermedades del Sistema Nervioso/tratamiento farmacológico , Enfermedades del Sistema Nervioso/metabolismo , Oxidación-ReducciónRESUMEN
Iodonium-class flavoprotein dehydrogenase inhibitors have been demonstrated to possess antiproliferative potential and to inhibit reactive oxygen production in human tumor cells, although the mechanism(s) that explains the relationship between altered cell growth and the generation of reactive oxygen species (ROS) remains an area of active investigation. Because of the ability of these compounds to inhibit the activity of flavoprotein-containing epithelial NADPH oxidases, we chose to examine the effects of several iodonium-class flavoprotein inhibitors on human colon cancer cell lines that express high, functional levels of a single such oxidase (NADPH oxidase 1, or Nox1). We found that diphenyleneiodonium (DPI), di-2-thienyliodonium (DTI), and iodonium diphenyl inhibited the growth of Caco2, HT-29, and LS-174T colon cancer cells at concentrations (10-250nM for DPI, 0.5-2.5µM for DTI, and 155nM to 10µM for iodonium diphenyl) substantially lower than needed for DU145 human prostate cancer cells, which do not possess functional NADPH oxidase activity. Drug treatment was associated with decreased H2O2 production and diminished intracellular ROS levels, lasting up to 24h, after short-term (1-h) exposure to the iodonium analogs. Decreased tumor cell proliferation was caused, in part, by a profound block in cell cycle progression at the G1/S interface in both LS-174T and HT-29 cells exposed to either DPI or DTI; and the G1 block was produced, for LS-174T cells, by upregulation of p27 and a drug concentration-related decrease in the expression of cyclins D1, A, and E that was partially prevented by exogenous H2O2. Not only did DPI and DTI decrease intracellular ROS, they both also significantly decreased the mRNA expression levels of Nox1, potentially contributing to the prolonged reduction in tumor cell reactive oxygen levels. We also found that DPI and DTI significantly decreased the growth of both HT-29 and LS-174T human tumor xenografts, at dose levels that produced peak plasma concentrations similar to those utilized for our in vitro experiments. These findings suggest that iodonium analogs have therapeutic potential for NADPH oxidase-containing human colon cancers in vivo and that at least part of their antineoplastic mechanism of action may be related to targeting Nox1.
Asunto(s)
Ciclo Celular/efectos de los fármacos , Neoplasias del Colon/metabolismo , Flavoproteínas/antagonistas & inhibidores , NADPH Oxidasas/metabolismo , Compuestos Onio/farmacología , Especies Reactivas de Oxígeno/metabolismo , Tiofenos/farmacología , Animales , Línea Celular Tumoral , Proliferación Celular/efectos de los fármacos , Ciclinas/biosíntesis , Puntos de Control de la Fase G1 del Ciclo Celular/efectos de los fármacos , Expresión Génica , Humanos , Peróxido de Hidrógeno/metabolismo , Masculino , Ratones , NADPH Oxidasa 1 , NADPH Oxidasas/genética , Trasplante de Neoplasias , Neoplasias de la Próstata/metabolismo , ARN Mensajero/biosíntesis , Trasplante HeterólogoAsunto(s)
Aniones/química , Electrones , Flavoproteínas/antagonistas & inhibidores , Cristalografía por Rayos X , Mononucleótido de Flavina/química , Flavina-Adenina Dinucleótido/química , Flavoproteínas/metabolismo , Oxidorreductasas/antagonistas & inhibidores , Oxidorreductasas/química , Estructura Terciaria de Proteína , Riboflavina/químicaRESUMEN
A role for the flavoprotein NRH:quinone oxidoreductase 2 (NQO2, QR2) in human diseases such as malaria, leukemia and neurodegeneration has been proposed. In order to explore the potential of NQO2 as a therapeutic target, we have developed potent and selective mechanism-based inhibitors centered on the indolequinone pharmacophore. The compounds show remarkable selectivity for NQO2 over the closely related flavoprotein NQO1, with small structural changes defining selectivity. Biochemical studies confirmed the mechanism-based inhibition, whereas X-ray crystallography and mass spectrometry revealed the nature of the inhibitor interaction with the protein. These indolequinones represent the first mechanism-based inhibitors of NQO2, and their novel mode of action involving alkylation of the flavin cofactor, provides significant advantages over existing competitive inhibitors in terms of potency and irreversibility, and will open new opportunities to define the role of NQO2 in disease.
Asunto(s)
Flavoproteínas/antagonistas & inhibidores , Indolquinonas/farmacología , NAD(P)H Deshidrogenasa (Quinona)/antagonistas & inhibidores , Quinona Reductasas/antagonistas & inhibidores , Dominio Catalítico , Cristalografía por Rayos X , Inhibidores Enzimáticos/química , Inhibidores Enzimáticos/farmacología , Humanos , Indolquinonas/química , Estructura Molecular , NAD(P)H Deshidrogenasa (Quinona)/genética , Quinona Reductasas/genética , Quinona Reductasas/metabolismo , Proteínas Recombinantes/genética , Especificidad por SustratoRESUMEN
NAD(P)H oxidases (NOXs) are a family of enzymes catalyzing the univalent reduction of oxygen to produce the superoxide anion radical, which in turn can be converted in other reactive oxygen species (ROS) and may participate to the formation of reactive nitrogen derivatives, such as peroxynitrite. By virtue of their activity, NOXs may represent a double-edged sword for the organism's homeostasis. On one hand ROS participate in host defence by killing invading microbes and may regulate several important physiological functions, such as cell signalling, regulation of cell growth and differentiation, oxygen sensing, angiogenesis, fertilization and control of vascular tone. On the other hand ROS may play an important role in pathological processes such as hypertension, atherosclerosis, diabetes, cancer, ischemia/reperfusion injury, neurodegenerative diseases. Many roles suggested for NOXs in various tissues and physiopathological situations have been inferred by the in vitro and in vivo effects of several NOX inhibitors. In particular, most studies are based on the use of two compounds, diphenyleneiodonium and apocynin. Aim of this review is to describe the main features of these two compounds, to show that they cannot be used as specific NOX inhibitors and to solicit researchers to find other tools for investigating the role of NOXs.
Asunto(s)
Inhibidores Enzimáticos/farmacología , NADPH Oxidasas/antagonistas & inhibidores , Acetofenonas/farmacología , Animales , Flavoproteínas/antagonistas & inhibidores , Humanos , Óxido Nítrico/biosíntesis , Compuestos Onio/farmacología , Estrés Oxidativo , Especies de Nitrógeno Reactivo/metabolismo , Especies Reactivas de Oxígeno/metabolismoRESUMEN
We previously reported that neutrophil elastase (NE) stimulated MUC1 gene expression in A549 lung epithelial cells through binding of Sp1 to the MUC1 promoter element. The current study was undertaken to elucidate the complete signaling pathway leading to Sp1 activation. Using a combination of pharmacologic inhibitors, dominant-negative mutant, RNA interference, and soluble receptor blocking techniques, we identified a protein kinase Cdelta (PKCdelta) --> dual oxidase 1 (Duox1) --> reactive oxygen species (ROS) --> TNF-alpha-converting enzyme (TACE) --> TNF-alpha --> TNF receptor (TNFR)1 --> extracellular signal-regulated kinase (ERK)1/2 --> Sp1 pathway as responsible for NE-activated MUC1 transcription. This cascade was identical up to the point of TACE with the signaling pathway previously reported for NE-stimulated MUC5AC production. However, unlike the MUC5AC pathway, TNF-alpha, TNFR1, ERK1/2, and Sp1 were unique components of the MUC1 pathway. Given the anti-inflammatory role of MUC1 during airway bacterial infection, up-regulation of MUC1 by inflammatory mediators such as NE and TNF-alpha suggests a crucial role for MUC1 in the control of excessive inflammation during airway bacterial infection.
Asunto(s)
Elastasa de Leucocito/metabolismo , Mucina-1/genética , Transducción de Señal , Transcripción Genética , Proteínas ADAM/metabolismo , Proteína ADAM17 , Línea Celular Tumoral , Células Cultivadas , Oxidasas Duales , Activación Enzimática/efectos de los fármacos , Inhibidores Enzimáticos/farmacología , Células Epiteliales/efectos de los fármacos , Células Epiteliales/metabolismo , Receptores ErbB/metabolismo , Quinasas MAP Reguladas por Señal Extracelular/metabolismo , Flavoproteínas/antagonistas & inhibidores , Regulación Neoplásica de la Expresión Génica/efectos de los fármacos , Humanos , Modelos Biológicos , NADPH Oxidasas/antagonistas & inhibidores , FN-kappa B/metabolismo , Fosfotreonina/metabolismo , Proteína Quinasa C-delta/antagonistas & inhibidores , Especies Reactivas de Oxígeno/metabolismo , Receptores Tipo I de Factores de Necrosis Tumoral/metabolismo , Factor de Transcripción Sp1/metabolismo , Transcripción Genética/efectos de los fármacosRESUMEN
Cryptochromes are blue-light receptors controlling multiple aspects of plant growth and development. They are flavoproteins with significant homology to photolyases, but instead of repairing DNA they function by transducing blue light energy into a signal that can be recognized by the cellular signaling machinery. Here we report the effect of cry1 and cry2 blue light receptors on primary root growth in Arabidopsis thaliana seedlings, through analysis of both cryptochrome-mutant and cryptochrome-overexpressing lines. Cry1 mutant seedlings show reduced root elongation in blue light while overexpressing seedlings show significantly increased elongation as compared to wild type controls. By contrast, the cry2 mutation has the opposite effect on root elongation growth as does cry1, demonstrating that cry1 and cry2 act antagonistically in this response pathway. The site of cryptochrome signal perception is within the shoot, and the inhibitor of auxin transport, 1-N-naphthylphthalamic acid, abolishes the differential effect of cryptochromes on root growth, suggesting the blue-light signal is transmitted from the shoot to the root by a mechanism that involves auxin. Primary root elongation in blue light may thereby involve interaction between cryptochrome and auxin signaling pathways.
Asunto(s)
Arabidopsis/crecimiento & desarrollo , Flavoproteínas/fisiología , Luz , Raíces de Plantas/crecimiento & desarrollo , Plantones/crecimiento & desarrollo , Arabidopsis/genética , Proteínas de Arabidopsis , Criptocromos , Técnicas de Cultivo , Flavoproteínas/antagonistas & inhibidores , Flavoproteínas/genética , Expresión Génica , Ácidos Indolacéticos/metabolismo , MutaciónRESUMEN
Sea urchin fertilization is marked by a massive conversion of molecular oxygen to hydrogen peroxide by a sea urchin dual oxidase, Udx1. This enzyme is essential for completing the physical block to polyspermy. Yet, its expression is maintained during development, as indicated by the presence of both Udx1 mRNA and Udx1 protein enriched at the surface of all non-mesenchymal blastomeres. When hydrogen peroxide synthesis by Udx1 is inhibited, either pharmacologically or by specific antibody injection, cleavage is delayed. Application of exogenous hydrogen peroxide, however, partially rescues a fraction of these defective embryos. We also report an unequal distribution of reactive oxygen species between sister blastomeres during early cleavage stages, suggesting a functional role for Udx1 in intracellular signaling.
Asunto(s)
Flavoproteínas/metabolismo , Lytechinus/metabolismo , NADPH Oxidasas/metabolismo , Especies Reactivas de Oxígeno/metabolismo , Animales , Blastómeros/enzimología , Blastómeros/metabolismo , Calcio/metabolismo , Flavoproteínas/antagonistas & inhibidores , Flavoproteínas/genética , Peróxido de Hidrógeno/metabolismo , Peróxido de Hidrógeno/farmacología , Lytechinus/embriología , Lytechinus/enzimología , NADPH Oxidasas/antagonistas & inhibidores , NADPH Oxidasas/genéticaRESUMEN
Hydrogen peroxide (H(2)O(2)) is found in exhaled breath and is produced by airway epithelia. In addition, H(2)O(2) is a necessary substrate for the airway lactoperoxidase (LPO) anti-infection system. To investigate the source of H(2)O(2) produced by airway epithelia, PCR was used to screen nicotinamide adenine dinucleotide phosphate (NADPH) oxidase expression in human airway epithelia redifferentiated at the air-liquid interface (ALI) and demonstrated the presence of Duox1 and 2. Western blots of culture extracts indicated strong expression of Duox, and immunohistochemistry of human tracheal sections localized the protein to the apical portion of epithelial cells. Apical H(2)O(2) production was stimulated by 100 microM ATP or 1 microM thapsigargin, but not 100 microM ADP. Diphenyleneiodonium, an NADPH oxidase inhibitor, and dimethylthiourea, a reactive oxygen species scavenger, both inhibited this stimulation. ATP did not stimulate the basolateral H(2)O(2) production by ALI cultures. ATP and thapsigargin increased intracellular Ca(2+) with kinetics similar to increasing H(2)O(2) production, and thus consistent with the expected Ca(2+) sensitivity of Duox. These data suggest that Duox is the major NADPH oxidase expressed in airway epithelia and therefore a contributor of H(2)O(2) production in the airway lumen. In addition, the data suggest that extracellular H(2)O(2) production may be regulated by stimuli that raise intracellular Ca(2+).
Asunto(s)
Células Epiteliales/metabolismo , Flavoproteínas/metabolismo , Peróxido de Hidrógeno/metabolismo , NADPH Oxidasas/metabolismo , Oxidantes/metabolismo , Mucosa Respiratoria/citología , Calcio/metabolismo , Línea Celular , Polaridad Celular , Oxidasas Duales , Células Epiteliales/citología , Flavoproteínas/antagonistas & inhibidores , Flavoproteínas/genética , Peroxidasa de Rábano Silvestre/metabolismo , Humanos , NADPH Oxidasas/antagonistas & inhibidores , NADPH Oxidasas/genética , Oxazinas/metabolismo , Oxidación-Reducción , Mucosa Respiratoria/metabolismo , Tapsigargina/metabolismo , Tráquea/citología , Tráquea/metabolismoRESUMEN
Multiple apoptotic stimuli induce conformational changes in Bax, a proapoptotic protein from the Bcl-2 family and its deficiency is a frequent cause of chemoresistance in colon adenocarcinomas. Curcumin, a dietary compound from turmeric, is known to induce apoptosis in a variety of cancer cells. To understand the role of Bax in curcumin-induced apoptosis we used HCT116 human colon cancer cells with one allele of Bax gene (Bax+/-) and Bax knockout HCT116 (Bax-/-) cells in which Bax gene is inactivated by homologous recombination. Cell viability decreased in a concentration-dependent manner in Bax+/- cells treated with curcumin (0-50 microM) whereas only minimal changes in viability were observed in Bax-/- cells upon curcumin treatment. In Bax-/- cells curcumin-induced activation of caspases 9 and 3 was blocked and that of caspase 8 remained unaltered. Curcumin-induced release of cytochrome c, Second mitochondria derived activator of caspase (Smac) and apoptosis inducing factor (AIF) was also blocked in Bax-/- cells and reintroduction of Bax, downregulation of the antiapoptotic protein Bcl-XL by antisense DNA as well as the overexpression of Smac, highly sensitized the Bax-/- cells toward curcumin-induced apoptosis. There was no considerable difference in the percentage of apoptotic cells in Bak RNAi transfected Bax+/- or Bax-/- cells treated with curcumin when compared with their corresponding vector transfected cells treated with curcumin. The present study demonstrates the role of Bax but not Bak as a critical regulator of curcumin-induced apoptosis and implies the potential of targeting antiapoptotic proteins like Bcl-XL or overexpression of proapoptotic proteins like Smac as interventional approaches to deal with Bax-deficient chemo-resistant cancers for curcumin-based therapy.
Asunto(s)
Antineoplásicos/farmacología , Apoptosis/efectos de los fármacos , Neoplasias del Colon/metabolismo , Curcumina/farmacología , Glicoproteínas/metabolismo , Proteínas Proto-Oncogénicas c-bcl-2/metabolismo , Proteínas Proto-Oncogénicas c-bcl-2/fisiología , Factor Inductor de la Apoptosis , Inhibidores de Caspasas , Caspasas/metabolismo , Neoplasias del Colon/patología , Complejo de Ataque a Membrana del Sistema Complemento , Proteínas del Sistema Complemento , Citocromos c/metabolismo , Regulación hacia Abajo , Resistencia a Antineoplásicos , Activación Enzimática/efectos de los fármacos , Flavoproteínas/antagonistas & inhibidores , Flavoproteínas/metabolismo , Glicoproteínas/antagonistas & inhibidores , Glicoproteínas/genética , Humanos , Proteínas de la Membrana/antagonistas & inhibidores , Proteínas de la Membrana/metabolismo , Oligonucleótidos Antisentido/farmacología , Proteínas Proto-Oncogénicas c-bcl-2/genética , Células Tumorales Cultivadas , Proteína X Asociada a bcl-2 , Proteína bcl-XRESUMEN
In acute myeloid leukemia (AML), resistance to chemotherapy is associated with defects in both the extrinsic and intrinsic pathways of apoptosis. Novel agents that activate endogenous apoptosis-inducing mechanisms directly may be potentially useful to overcome chemoresistance in AML. We examined the mechanisms of apoptosis induction by the novel synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO) in AML cells. CDDO-induced apoptosis was associated with the loss of mitochondrial inner transmembrane potential, caspases activation, the translocation of apoptosis-inducing factor to the nucleus, and DNA fragmentation in AML cells. Apoptosis was equally evident in cells deficient in caspase-9 or caspase-8 after exposure to CDDO, suggesting caspase-independent cell death. The use of small interfering RNA to reduce the expression of apoptosis-inducing factor partially inhibited CDDO-induced apoptosis in AML cells. Cells overexpressing Bcl-2 were markedly resistant to CDDO-induced apoptosis. Moreover, CDDO promoted the release of cytochrome c from isolated mitochondria, suggesting that CDDO targets the mitochondria directly to trigger the intrinsic pathway of cell death in intact cells. Together, these results suggest that CDDO functions by activating the intrinsic pathway of apoptosis and initiates caspase-dependent and independent cell death. The direct modulation of mitochondrial-mediated, caspase-independent apoptosis by CDDO may be advantageous for overcoming chemoresistance in AML.
Asunto(s)
Antineoplásicos/farmacología , Apoptosis/efectos de los fármacos , Caspasas/fisiología , Leucemia Mieloide Aguda/tratamiento farmacológico , Ácido Oleanólico/análogos & derivados , Ácido Oleanólico/farmacología , Factor Inductor de la Apoptosis , División Celular/efectos de los fármacos , Línea Celular , Flavoproteínas/antagonistas & inhibidores , Flavoproteínas/fisiología , Humanos , Leucemia Mieloide Aguda/patología , Potenciales de la Membrana/efectos de los fármacos , Proteínas de la Membrana/antagonistas & inhibidores , Proteínas de la Membrana/fisiología , Mitocondrias/efectos de los fármacos , Mitocondrias/fisiología , PPAR gamma/fisiología , Fosfatidilserinas/metabolismo , Proteínas Proto-Oncogénicas c-bcl-2/fisiologíaRESUMEN
Because proliferation of eukaryotic cells requires cell cycle-regulated chromatid separation by the mitotic spindle, it is subject to regulation by mitotic checkpoints. To determine the mechanism of the antiproliferative activity of the flavoprotein-specific inhibitor diphenyleneiodonium (DPI), I have examined its effect on the cell cycle and mitosis. Similar to paclitaxel, exposure to DPI causes an accumulation of cells with a 4N DNA content. However, unlike the paclitaxel-mediated mitotic block, DPI-treated cells are arrested in the cell cycle prior to mitosis. Although DPI-treated cells can arrest with fully separated centrosomes at opposite sides of the nucleus, these centrosomes fail to assemble mitotic spindle microtubules and they do not accumulate the Thr(288) phosphorylated Aurora-A kinase marker of centrosome maturation. In contrast with paclitaxel-arrested cells, DPI impairs cyclin B1 accumulation. Release from DPI permits an accumulation of cyclin B1 and progression of the cells into mitosis. Conversely, exposure of paclitaxel-arrested mitotic cells to DPI causes a precipitous drop in cyclin B and Thr(288) phosphorylated Aurora-A levels and leads to mitotic catastrophe in a range of cancerous and noncancerous cells. Hence, the antiproliferative activity of DPI reflects a novel inhibitory mechanism of cell cycle progression that can reverse spindle checkpoint-mediated cell cycle arrest.
Asunto(s)
Ciclina B/biosíntesis , Regulación hacia Abajo , Flavoproteínas/antagonistas & inhibidores , Fase G2 , Mitosis , Compuestos Onio/farmacología , Animales , Antioxidantes/metabolismo , Antioxidantes/farmacología , Apoptosis , Aurora Quinasa A , Aurora Quinasas , Western Blotting , Ciclo Celular , Proteínas de Ciclo Celular , Línea Celular , Línea Celular Tumoral , Proliferación Celular , Centrosoma/metabolismo , Centrosoma/ultraestructura , Cromátides/metabolismo , Ciclina B/metabolismo , Ciclina B1 , ADN/metabolismo , Inhibidores Enzimáticos/farmacología , Citometría de Flujo , Humanos , Sistema de Señalización de MAP Quinasas , Ratones , Microscopía Confocal , Microscopía Fluorescente , Microscopía de Contraste de Fase , Células 3T3 NIH , Paclitaxel/farmacología , Fosforilación , Proteínas Quinasas/metabolismo , Proteínas Serina-Treonina Quinasas , Ratas , Especies Reactivas de Oxígeno/metabolismo , Huso Acromático/metabolismo , Treonina/química , Factores de Tiempo , Proteínas de XenopusRESUMEN
IL-4-induced gene-1 (Il4i1 or Fig1) initially isolated as a gene of unknown function from mouse B lymphocytes, is limited in expression to primarily immune tissues and genetically maps to a region of susceptibility to autoimmune disease. The predicted Il4i1 protein (IL4I1) sequence is most similar to apoptosis-inducing protein and Apoxin I, both l-amino acid oxidases (LAAO; Enzyme Commission 1.4.3.2). We demonstrate that IL4I1 has unique LAAO properties. IL4I1 has preference for aromatic amino acid substrates, having highest specific activity with phenylalanine. In support of this selectivity, IL4I1 is inhibited by aromatic competitors (benzoic acid and para-aminobenzoic acid), but not by nonaromatic LAAO inhibitors. Il4i1 protein and enzyme activity is found in the insoluble fraction of transient transfections, implying an association with cell membrane and possibly intracellular organelles. Indeed, IL4I1 has the unique property of being most active at acidic pH (pH 4), suggesting it may reside preferentially in lysosomes. IL4I1 is N-linked glycosylated, a requirement for lysosomal localization. Confocal microscopy of cells expressing IL4I1 translationally fused to red fluorescent protein demonstrated that IL4I1 colocalized with GFP targeted to lysosomes and with acriflavine, a green fluorescent dye that is taken up into lysosomes. Thus, IL4I1 is a unique mammalian LAAO targeted to lysosomes, an important subcellular compartment involved in Ag processing.